Gilgamesh Pharmaceuticals
Held clinical and research positions at the Connecticut Mental Health Center and the West Haven VA Medical Center, while on faculty at Yale and focused on translational research and novel treatments for affective disorders. This work includes the first report on the clinical efficacy of the non-specific glutamate NMDA antagonist, ketamine, in the treatment of depression (Berman et al., 2000).
This person is not in any offices
Gilgamesh Pharmaceuticals
Gilgamesh is a pioneering early-stage biotech developing novel compounds that build upon the benefits of classic psychedelics with improvements of other components such as safety, tolerability, duration, and efficacy.